Drug Trial Radar · NCT06206837
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
71
Actual
Start
Feb 19, 2024
Primary completion
Sep 5, 2025
Study completion May 25, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Arvinas Estrogen Receptor, Inc.
- First posted
- Jan 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat. The study is seeking for participants who have breast cancer that: * is hard to treat (advanced) and may have spread to other organs (metastatic). * is sensitive to hormonal therapy (it is called estrogen receptor positive). * is no longer responding to treatments taken before starting this study. All the participants will receive vepdegestrant and PF-07220060. Both medicines will be taken by mouth. The medicines will be taken at home. The experience of people receiving the study medicines will be studied. This will help see if the study medicines are safe and effective. Participants will continue to take vepdegestrant and PF-07220060 until: * their cancer is no longer responding, or * side effects become too severe. They will have visits at the study clinic about every 4 weeks.
Conditions
- Breast Cancer
Interventions
vepdegestrantDrug
Daily oral dosages of vepdegestrant continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
PF-07220060Drug
Daily oral dosages of PF-07220060 continuously, dose escalation/de-escalation in Phase 1b until recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose-Limiting Toxicities (DLTs): Phase 1bTime frame: Cycle 1 (28 days)
- Percentage of Participants With Confirmed Objective Response (OR) by Derived Investigator Assessment: Phase 2Time frame: From the date of first dose of study treatment combination until the first documentation of disease progression (PD), death or start of new anticancer therapy, whichever occurred first (maximum treatment exposure of 9.5 months for Phase 2)
Locations
58 sites in 8 countries. Site status is shown where the registry gives one.
Highlands Oncology
Fayetteville, Arkansas
Highlands Oncology
Rogers, Arkansas
Highlands Oncology Group
Springdale, Arkansas
Hoag Health Center Irvine
Irvine, California
Hoag Hospital Irvine
Irvine, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Clinical and Translational Research Unit (CTRU)
Palo Alto, California
Stanford Cancer Center
Palo Alto, California
Stanford Cancer Institute - Clinical Trials Office
Palo Alto, California
UCSF Medical Center at Mission Bay
San Francisco, California
UCHealth Poudre Valley Hospital
Fort Collins, Colorado
UCHealth Harmony
Fort Collins, Colorado
UCHealth Greeley Hospital
Greeley, Colorado
UCHealth - Medical Center of the Rockies
Loveland, Colorado
Smilow Cancer Hospital - Yale New Haven Health
New Haven, Connecticut
Yale - New Haven Hospital - Yale Cancer Center
New Haven, Connecticut
Smilow Cancer Hospital Phase 1 Unit
New Haven, Connecticut
Smilow Cancer Hospital - Trumbull
Trumbull, Connecticut
START Midwest
Grand Rapids, Michigan
MSK Basking Ridge
Basking Ridge, New Jersey
MSK Monmouth
Middletown, New Jersey
MSK Bergen
Montvale, New Jersey
MSK Commack
Commack, New York
MSK Westchester
Harrison, New York
Rockefeller Outpatient Pavilion (53rd Street)
New York, New York
Evelyn H. Lauder Breast and Imaging Center (BAIC).
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
MSK Nassau
Uniondale, New York
START San Antonio
San Antonio, Texas
University of Utah, Farmington Health Center
Farmington, Utah
University of Utah, Sugar House Health Center
Salt Lake City, Utah
Huntsman Cancer Institute
Salt Lake City, Utah
South Jordan Health Center - University of Utah
South Jordan, Utah
START Mountain Region
West Valley City, Utah
Antwerp University Hospital
Edegem, Antwerpen, Belgium
Institut Jules Bordet
Anderlecht, Bruxelles-capitale, Région de, Belgium
UZ Leuven
Leuven, Vlaams-brabant, Belgium
AZ Groeninge Campus Kennedylaan
Kortrijk, West-vlaanderen, Belgium
The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
Sunnybrook Research Institute
Toronto, Ontario, Canada
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.